PHILADELPHIA--(BUSINESS WIRE)--April 11, 2005-- Launch of SAS(R) Drug Development 3.0 Provides Unmatched Insight into Clinical Trials Through Powerful Data Integration and Analysis Bringing new therapies to market is extraordinarily complex, with clinical trials data scattered among different systems throughout life sciences research organizations and new data arriving almost continuously from electronic data capture (EDC) vendors, contract research organizations (CROs) and other research partners. At the same time, costs are escalating, budgets are tightening and the pressure from regulatory agencies, shareholders and consumers has never been greater. It is imperative that life sciences executives make intelligent decisions quickly and efficiently, and they can only do so if they have the utmost confidence in their clinical, data management and biostatistical information and processes. How can life sciences companies fully integrate and analyze their research for regulatory submission, and identify new market opportunities and product line extensions - all while addressing potential safety issues more efficiently and effectively?
